This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Exforge HCT Combo
Drug Names(s): Diovan/Exforge/Valsartan/Imprida/Dafiro/Copalia + amlodipine + hydrochlorothiazide (HCT), Dafiro HCT
Description: Valsartan/amlodipine/hydrochlorothiazide is a combination of the angiotensin II receptor antagonist valsartan (Diovan), the calcium channel blocker amlodipine, and the diuretic hydrochlorothiazide. Valsartan inhibits the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Aldosterone acts on the kidneys to increase retention of sodium and fluid, and on the central nervous system to increase thirst. Amlodipine dilate blood vessels. Hydrochlorothiazide also acts on the kidneys to reduce resorption of sodium and fluid.
Deal Structure: Exforge HCT was originally developed by Novartis.
In August 2009, UCB and Novartis announced that they entered into a licensing agreement for cardiovascular and diabetes products in Germany. Under the agreement, UCB licensed in commercial rights for Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT).
Partners: UCB SA
Exforge HCT Combo News
Additional information available to subscribers only: